PacificHealth Laboratories Enters Into an Agreement With Eric Harr, Founder and President of Resonate Social Media
06 Dicembre 2011 - 3:00PM
Marketwired
PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading nutrition
technology company, announced today that it has entered into an
agreement with Eric Harr, Founder and President of Resonate Social
Media, to manage the Company's social media & digital marketing
campaign for 2012.
Fred Duffner, CEO and President of PacificHealth Laboratories,
said, "Eric Harr is widely-recognized as one of the leading social
strategists in the world. Eric has designed and deployed highly
successful integrated social campaigns for dozens of multinational
companies. We believe that Eric will play a pivotal role in helping
PHLI expand our ecommerce business."
Resonate Media, the company founded by Mr. Harr, is a highly
successful boutique social media agency whose clients include HP,
The Four Seasons, and Lexus. Mr. Harr has helped his clients
establish and scale their social communities with engaged audience
reach into the tens of millions. He has successfully integrated
social media with traditional marketing strategies and measured
non-financial outcomes, as well as financial impact, using an
industry-leading proprietary dashboard technology he co-developed
called "SocialSee." The technology is the first to calculate, in
real-time, a company's Return on Investment (ROI) from social
media. Mr. Harr is the author of the national best-selling book,
The Real Truth About Social Media: 8 Timeless Truths Revealed and 8
Monumental Myths Uncovered, and serves as the social media expert
on CBS News' Bay Sunday. He is also a professional triathlete who
finished 40th in the Hawaiian Ironman 2011 Championships.
Mr. Harr said, "The products of PacificHealth Laboratories
literally powered my finish in the Hawaiian Ironman. The following
week I approached Fred and literally begged him to take on their
social media. PacificHealth Labs is a legacy brand. With a powerful
social media presence, I am confident we will be able to drive
growth in 2012 and beyond."
Fred Duffner continued, "Although we have made a great deal of
progress over the past two years, we recognize we have just begun
to realize the ecommerce potential for our business. Our new
partnership with Eric ensures we have the right leadership and
direction to help us fully recognize the potential."
About PacificHealth: PacificHealth
Laboratories, Inc. (OTCQB: PHLI), a leading nutrition technology
company, has been a pioneer in discovering, developing and
commercializing patented, protein-based nutritional products that
stimulate specific peptides involved in appetite regulation and
that activate biochemical pathways involved in muscle performance
and growth. PHLI's principal areas of focus include sports
performance and weight loss. To learn more, visit
www.pacifichealthlabs.com.
Notice: This news release and oral statements made from time to
time by Company representatives concerning the same subject matter
may contain so-called "forward-looking statements." These
statements can be identified by introductory words such as
"expects," "plans," "will," "estimates,", "forecasts," "projects,"
or words of similar meaning and by the fact they do not relate
strictly to historical or current facts. Forward-looking statements
frequently are used in discussing new products and their potential.
Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a
broad variety of risks and uncertainties, some of which are known,
such as general economic conditions, consumer product acceptance
and competitive products, and others of which are not. No
forward-looking statements are a guarantee of future results or
events, and one should avoid placing undue reliance on such
statements.
Contact: Stephen Kuchen 732-739-2900, x603 Email Contact
Grafico Azioni PacificHealth Laboratories (CE) (USOTC:PHLI)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni PacificHealth Laboratories (CE) (USOTC:PHLI)
Storico
Da Feb 2024 a Feb 2025